Sovremennyy vzglyad na antianginal'nuyu terapiyu bol'nykh ishemicheskoy bolezn'yu serdtsa
- Авторлар: Privalova E.V1
-
Мекемелер:
- Шығарылым: № 13 (2015)
- Беттер: 50-53
- Бөлім: Articles
- URL: https://journals.eco-vector.com/2073-4034/article/view/288113
- ID: 288113
Дәйексөз келтіру
Ашық рұқсат
Рұқсат берілді
Аннотация
The main target of anti-anginal and anti-ischemic therapy in patients with stable coronary artery disease (CAD) is the elimination of clinical symptom - angina pectoris. However, assessment of the effectiveness of such treatment should be performed taking into account variants of clinical manifestations of stable coronary artery disease course. According to European guidelines 2013, the arsenal of the practitioner includes two groups of drugs for the antianginal therapy. The first group consists of β-blockers, nondihydropyridine and dihydropyridine calcium antagonists. The second group includes nitrates, ivabradine, ranolazine and nicorandil, and trimetazidine. The use of combinations of recommended antianginal drugs allows to significantly increase the effectiveness of treatment of patients with coronary artery disease and their quality of life.
Негізгі сөздер
Толық мәтін
Әдебиет тізімі
- ESC guidlines. Eur. Heart J. Advance Access published August 2013.
- Fox K., Ford I., Steg P.G., Tardif J.C., Tendera M., Ferrari R. Ivabradine in stable coronary artery disease without clinical heart failure. N. Engl. J. Med. 2014;371(12):1091-99.
- Yusuf S., Wittes J, Friedman L. Overview of results of randomized clinical trials in heart disease. I. Treatments following myocardial infarction. JAMA. 1988;260:2088-93.
- Gori T., Floras J.S., Parker J.D. Effects of Nitroglycerin Treatment on Barore ex Sensitivity and Short-Term Heart Rate Variability in Humans. J. Am. Coll. Cardiol. 2002;40:2000-05.
- Gori T., Parker J.D. The Puzzle of Nitrate TolerancePieces Smaller Than We Thought? Circulation. 2002;106:2404-08.
- Münzel T., Daiber A., Gori T. Nitrate Therapy. New Aspects Concerning Molecular Action and Tolerance. Circ. Res. 2005;97:618-28.
- Fox K., Ford I., Steg P.G., Tendera M., Ferrari R. Relationship between ivabradine treatment and cardiovascular outcomes in patients with stable coronary artery disease and left ventricular systolic dysfunction with limiting angina: a subgroup analysis of the randomized, controlled BEAUTIFUL trial. Eur. Heart J. 2009;30(19):2337-45.
- Tardif J.C., Ponikowski P., Kahan T. Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebocontrolled trial. Eur. Heart J. 2009;30:540-48.
- The IONA Study Group. Lancet. 2002;359:1269-75.
- Chaitman B.R., Pepine C.J., Parker J.O., Skopal J., Chumakova G., Kuch J. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004;291:309-16.
- Stone P, Gratsiansky N.A., Blokhin A., Huang I.Z., Meng L. Antianginal efficacy of ranolazine when added to treatment with amlodipine: the ERICA (Efficacy of Ranolazine in Chronic Angina) trial. J. Am. Coll. Cardiol. 2006;48(3): 566-75.
- Koren M.J., Crager M.R., Sweeney M. Long-term safety of a novel antianginal agent in patients with severe chronic stable angina: the Ranolazine Open Label Experience (ROLE). J. Am. Coll. Cardiol. 2007;49:1027-34.
- Morrow D., Scirica B.M., Chaitman B.R. Utility of ranolazine in chronic stable angina patients. JAMA. 2007;297:1775-83.
- Nesukay E. The benefits of adding Trimetazidine MR to beta-blockers in agina patients. Circulation. 2012;125:e773.
- Di Napoli P., Di Giovanni P., Gaeta M.A. Advantages of Preduktal MR in treatment of patients with coronary heart disease J. Cardiovasc. Pharmacol. 2007;50(5):585-89.
- Бубнова М.Г, Аронов Д.М., Оганов Р.Г. Влияние терапии триметазидином на показатели переносимости физической нагрузки и качество жизни пациентов со стабильной стенокардией, получающих оптимальную медикаментозную терапию. Кардиоваскулярная терапия и профилактика. 2011;6:70-80.
Қосымша файлдар
